SCHEMBL21055229

SCHEMBL21055229

O=C1CCC(Oc2ccccc2F)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 8/20 0.51
HTR1A P08908 7/20 0.51
SLC6A3 Q01959 4/20 0.51
HTR2C P28335 1/20 0.43
LPAR1 Q92633 1/20 0.42
LPAR5 Q9H1C0 1/20 0.42
FPR2 P25090 1/20 0.42
PROKR1 Q8TCW9 1/20 0.42
SLC6A4 P31645 1/20 0.41
PDE4A P27815 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39
PDE4D Q08499 1/20 0.39
HPGD P15428 1/20 0.39
GRIN1 Q05586 2/20 0.39
GRIN2B Q13224 2/20 0.39
CACNB4 O00305 1/20 0.37
CACNA1A O00555 1/20 0.37
CACNA1G O43497 1/20 0.37
CACNG3 O60359 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29966 0.85 SLC6A2 (0.61) SLC6A2HTR1ASLC6A3HTR2CLPAR1
SCHEMBL17123797 0.81 SLC6A2 (0.57) SLC6A2HTR1ASLC6A3HTR2CLPAR1
SCHEMBL9538522 0.79 SLC6A2 (0.56) SLC6A2HTR1ASLC6A3LPAR1LPAR5
SCHEMBL4699077 0.77 PDE4A (0.41) SLC6A2HTR1ASLC6A3SLC6A4PDE4A
SCHEMBL16571016 0.76 SLC6A2 (0.53) SLC6A2HTR1ASLC6A3HTR2CLPAR1
SCHEMBL18186077 0.76 SLC6A2 (0.53) SLC6A2HTR1ASLC6A3HTR2CLPAR1
SCHEMBL12181083 0.76 SLC6A2 (0.53) SLC6A2HTR1ASLC6A3HTR2CLPAR1
SCHEMBL234010 0.76 SLC6A2 (0.81) SLC6A2HTR1ASLC6A3HTR2CSLC6A4
SCHEMBL2298389 0.76 SLC6A2 (0.53) SLC6A2HTR1ASLC6A3HTR2CLPAR1
SCHEMBL21047681 0.76 MEN1 (0.47) SLC6A2SLC6A3SLC6A4PDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11247990-B1 Bicyclic fused pyridine compounds as inhibitors of TAM kinases ARRAY BIOPHARMA INC (US) 2022-02-15 US disclosed
WO-2019113190-A1 BICYCLIC FUSED PYRIDINE COMPOUNDS AS INHIBITORS OF TAM KINASES ARRAY BIOPHARMA INC. (US) 2019-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11247990-B1 Bicyclic fused pyridine compounds as inhibitors of TAM kinases MAP3K1, MAP3K3, MAP3K2 SLC6A2 3958/4885HTR1A 2149/4885SLC6A3 3041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.